Loading company…
Mana Bio develops lipid nanoparticle delivery systems for vaccines and gene therapies.
Mana Bio combines machine learning and nanotechnology to develop lipid nanoparticle drug delivery systems for vaccines and gene therapies, including DNA- and RNA-based treatments. Founded in 2021, the company is based in Israel. In October 2023, it raised USD 19.5 million in Seed funding co-led by Base4 Capital, Andreessen Horowitz, and Technion - Israel Institute of Technology, with NFX and Lion Bird Fund participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in